Needham & Company LLC Raises Artivion (NYSE:AORT) Price Target to $58.00

Artivion (NYSE:AORT) had its price target upped by investment analysts at Needham & Company LLC from $50.00 to $58.00 in a report released on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price target points to a potential upside of 27.15% from the stock’s previous close.

A number of other equities analysts have also issued reports on AORT. Wall Street Zen upgraded shares of Artivion from a “hold” rating to a “buy” rating in a research report on Monday, August 25th. Oppenheimer reaffirmed an “outperform” rating on shares of Artivion in a research note on Friday, August 8th. Citigroup reiterated an “outperform” rating on shares of Artivion in a report on Friday, October 10th. Canaccord Genuity Group boosted their price objective on Artivion from $41.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, September 29th. Finally, LADENBURG THALM/SH SH lowered shares of Artivion from a “buy” rating to a “neutral” rating and raised their target price for the company from $32.00 to $38.80 in a research note on Wednesday, August 13th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $48.97.

Artivion Price Performance

AORT stock traded down $1.89 during midday trading on Friday, reaching $45.62. 94,594 shares of the company’s stock traded hands, compared to its average volume of 431,618. The company has a 50-day simple moving average of $42.42 and a two-hundred day simple moving average of $35.25. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52. Artivion has a 1-year low of $21.97 and a 1-year high of $47.69. The company has a market cap of $2.15 billion, a price-to-earnings ratio of -108.61 and a beta of 1.65.

Artivion (NYSE:AORT) last announced its earnings results on Thursday, November 6th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.14 by $0.02. The company had revenue of $113.39 million for the quarter, compared to analysts’ expectations of $110.71 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The company’s revenue was up 18.9% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. On average, analysts anticipate that Artivion will post 0.37 earnings per share for the current year.

Insiders Place Their Bets

In related news, SVP Jean F. Holloway sold 23,356 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $43.01, for a total value of $1,004,541.56. Following the completion of the transaction, the senior vice president directly owned 172,129 shares in the company, valued at approximately $7,403,268.29. The trade was a 11.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Marshall S. Stanton sold 18,200 shares of the stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $44.02, for a total transaction of $801,164.00. Following the sale, the senior vice president directly owned 64,200 shares of the company’s stock, valued at $2,826,084. This represents a 22.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 74,858 shares of company stock worth $3,250,129. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in shares of Artivion by 8.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,029,059 shares of the company’s stock worth $128,250,000 after purchasing an additional 232,424 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Artivion by 338.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 122,199 shares of the company’s stock valued at $5,174,000 after acquiring an additional 94,312 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Artivion by 6.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company’s stock worth $349,000 after purchasing an additional 477 shares during the last quarter. Public Sector Pension Investment Board raised its holdings in shares of Artivion by 23.7% in the 3rd quarter. Public Sector Pension Investment Board now owns 161,970 shares of the company’s stock valued at $6,858,000 after purchasing an additional 30,989 shares during the period. Finally, Illinois Municipal Retirement Fund lifted its stake in Artivion by 4.0% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 21,535 shares of the company’s stock valued at $912,000 after purchasing an additional 829 shares during the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.